Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2015 | Pages:
106 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Retinal Vein Occlusion - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Retinal Vein Occlusion - Pipeline Review, H1 2015', provides an overview of the Retinal Vein Occlusion's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Retinal Vein Occlusion, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinal Vein Occlusion and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Retinal Vein Occlusion - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Retinal Vein Occlusion and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Retinal Vein Occlusion products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Retinal Vein Occlusion pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reason to Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Retinal Vein Occlusion - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Retinal Vein Occlusion pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Retinal Vein Occlusion Overview 8 Therapeutics Development 9 Pipeline Products for Retinal Vein Occlusion - Overview 9 Pipeline Products for Retinal Vein Occlusion - Comparative Analysis 10 Retinal Vein Occlusion - Therapeutics under Development by Companies 11 Retinal Vein Occlusion - Therapeutics under Investigation by Universities/Institutes 12 Retinal Vein Occlusion - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Retinal Vein Occlusion - Products under Development by Companies 16 Retinal Vein Occlusion - Products under Investigation by Universities/Institutes 17 Retinal Vein Occlusion - Companies Involved in Therapeutics Development 18 Aerpio Therapeutics, Inc. 18 Allergan, Inc. 19 Avalanche Biotechnologies, Inc. 20 F. Hoffmann-La Roche Ltd. 21 Kala Pharmaceuticals, Inc. 22 Mabion SA 23 NicOx S.A. 24 Ohr Pharmaceutical Inc. 25 pSivida Corp. 26 Regeneron Pharmaceuticals, Inc. 27 ThromboGenics NV 28 Retinal Vein Occlusion - Therapeutics Assessment 29 Assessment by Monotherapy Products 29 Assessment by Target 30 Assessment by Mechanism of Action 33 Assessment by Route of Administration 35 Assessment by Molecule Type 37 Drug Profiles 39 aflibercept (recombinant) - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 AKB-9778 - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 AVA-101 - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 beclomethasone dipropionate - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 fluocinolone acetonide - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 loteprednol etabonate - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 NCX-422 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 NCX-434 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 ocriplasmin (recombinant) - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 Peptides to Inhibit Phosphatidylserine for Central Retinal Vein Occlusion - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 ranibizumab - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 ranibizumab biosimilar - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 Recombinant Protein for Central Retinal Vein Occlusion - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 squalamine lactate - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 Retinal Vein Occlusion - Recent Pipeline Updates 64 Retinal Vein Occlusion - Discontinued Products 95 Retinal Vein Occlusion - Product Development Milestones 96 Featured News & Press Releases 96 Apr 23, 2015: ThromboGenics Starts Evaluating JETREA for the Treatment of Retinal Vein Occlusion 96 Feb 26, 2015: Bayer Receives EU Approval for EYLEA for the Treatment of Retinal Vein Occlusion 96 Dec 01, 2014: Bayer Receives Health Canada Approval For Eylea For Two Additional Indications 97 Sep 04, 2014: Regeneron Announces Submission of Application for EYLEA (aflibercept) Injection in Japan for Macular Edema Following Branch Retinal Vein Occlusion 98 Aug 11, 2014: Ohr Pharmaceutical Announces Squalamine Eye Drop (OHR-102) Phase II Clinical Data in Retinal Vein Occlusion 98 Jul 31, 2014: Kala Pharmaceuticals Initiates Phase 2 Clinical Trial to Evaluate LE-MPP (KPI-121) in Patients with Retinal Vein Occlusion and Diabetic Macular Edema 99 Jun 11, 2014: Bayer Submits Aflibercept Solution for Injection Into the Eye for Fourth Indication in EU 100 Nov 22, 2013: EYLEA Injection Approved For The Treatment of Macular Edema Following Central Retinal Vein Occlusion In Japan 100 Nov 12, 2013: Regeneron Highlights EYLEA (aflibercept) Injection Data to Be Presented at American Academy of Ophthalmology Annual Meeting 101 Sep 27, 2013: New data for Novartis drug Lucentis reinforces transformational efficacy and well-established safety profile across four indications 103 Appendix 105 Methodology 105 Coverage 105 Secondary Research 105 Primary Research 105 Expert Panel Validation 105 Contact Us 105 Disclaimer 106
List of Tables
Number of Products under Development for Retinal Vein Occlusion, H1 2015 9 Number of Products under Development for Retinal Vein Occlusion - Comparative Analysis, H1 2015 10 Number of Products under Development by Companies, H1 2015 11 Number of Products under Investigation by Universities/Institutes, H1 2015 12 Comparative Analysis by Late Stage Development, H1 2015 13 Comparative Analysis by Clinical Stage Development, H1 2015 14 Comparative Analysis by Early Stage Development, H1 2015 15 Products under Development by Companies, H1 2015 16 Products under Investigation by Universities/Institutes, H1 2015 17 Retinal Vein Occlusion - Pipeline by Aerpio Therapeutics, Inc., H1 2015 18 Retinal Vein Occlusion - Pipeline by Allergan, Inc., H1 2015 19 Retinal Vein Occlusion - Pipeline by Avalanche Biotechnologies, Inc., H1 2015 20 Retinal Vein Occlusion - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 21 Retinal Vein Occlusion - Pipeline by Kala Pharmaceuticals, Inc., H1 2015 22 Retinal Vein Occlusion - Pipeline by Mabion SA, H1 2015 23 Retinal Vein Occlusion - Pipeline by NicOx S.A., H1 2015 24 Retinal Vein Occlusion - Pipeline by Ohr Pharmaceutical Inc., H1 2015 25 Retinal Vein Occlusion - Pipeline by pSivida Corp., H1 2015 26 Retinal Vein Occlusion - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2015 27 Retinal Vein Occlusion - Pipeline by ThromboGenics NV, H1 2015 28 Assessment by Monotherapy Products, H1 2015 29 Number of Products by Stage and Target, H1 2015 32 Number of Products by Stage and Mechanism of Action, H1 2015 34 Number of Products by Stage and Route of Administration, H1 2015 36 Number of Products by Stage and Molecule Type, H1 2015 38 Retinal Vein Occlusion Therapeutics - Recent Pipeline Updates, H1 2015 64 Retinal Vein Occlusion - Discontinued Products, H1 2015 95
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
